The bill would authorize spending of approximately $8.1 billion on transit projects through 2015 while legislators plan a long-term bill that could have implications for the pharmaceutical industry.
The House voted 312-119 on July 14, 2015 to authorize spending for the Highway Trust Fund until the end of 2015. The deal proposes to inject approximately $8.1 billion into transit improvements in the short-term while legislators continue work on the details of a long-term plan involving the proposed repatriation of approximately $2 trillion held offshore by US companies, many of which include large pharmaceutical companies that have corporate tax havens overseas.
The long-term deal would rely on the repatriation of US businesses-including many in the pharmaceutical industry-to fund improvements in the country’s transportation and highway system. On a statement on his website, House Ways and Means Committee Chairman Paul Ryan supported the initiative, saying “the Senate should move quickly to adopt this extension-without any unrelated measures-so that we can provide some certainty and get to work on a multi-year plan.” A long-term, multi-year plan would require a few months to develop, Ryan said on the House floor, Reutersreports.
A bipartisan working group suggested in early July that US companies with corporate homes offshore should be able to repatriate funds at a rate lower than the current corporate tax rate. The group claims that while the Treasury Department’s recent anti-inversion policies have dissuaded continued inversions, more widespread tax reform is warranted.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.